Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EMA Moves Ahead With Tailored Scientific Advice For Biosimilars

Follows Success Of Pilot Scheme That Offered Biosimilar Applicants Development Advice

Executive Summary

A European Medicines Agency pilot scheme offering tailored scientific advice on biosimilar development has been viewed by applicants as a “valuable opportunity” and the process will continue as part of regular operations, according to an agency report.

You may also be interested in...



European Parliament Urges Increased Role For Generics And Biosimilars

A report adopted by the European Parliament calling for measures to support a “greater market presence for generic and biosimilar medicines” has been welcomed by Medicines for Europe.

MPP And WHO Announce COVID Technology License Via C-TAP

The WHO and Medicines Patent Pool have announced “the first transparent, global, non-exclusive license for a COVID-19 technology” after striking a deal for a COVID-19 serological antibody technology with the Spanish National Research Council through the WHO’s COVID-19 Technology Access Pool.

Consolidation And COVID See Off-Patent Industry Rankings Rewritten

After an extraordinary year that saw demand patterns and the supply chain upended by the COVID-19 pandemic, as well as a major merger that has transformed one of the global off-patent industry’s biggest players, Generics Bulletin’s Top 50 has once again seen significant changes.

Topics

UsernamePublicRestriction

Register

PS145152

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel